Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 7/20 | 0.45 |
| ▸ | THRB | P10828 | 7/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640506 | 0.86 | THRA (0.48) | THRATHRBL3MBTL1CNR1ALDH1A1 | |
| SCHEMBL1642407 | 0.85 | THRA (0.58) | THRATHRB | |
| SCHEMBL6738408 | 0.83 | THRA (0.51) | THRATHRBCNR1 | |
| SCHEMBL6854726 | 0.83 | THRB (0.43) | THRATHRBL3MBTL1CNR1ALDH1A1 | |
| SCHEMBL1642319 | 0.83 | THRA (0.59) | THRATHRB | |
| SCHEMBL6738420 | 0.83 | THRA (0.44) | THRATHRBL3MBTL1ALDH1A1GAA | |
| SCHEMBL1642411 | 0.83 | THRA (0.49) | THRATHRBL3MBTL1CNR1ALDH1A1 | |
| SCHEMBL7063019 | 0.83 | THRA (0.55) | THRATHRBCNR1 | |
| SCHEMBL6742192 | 0.82 | THRA (0.52) | THRATHRBGAA | |
| SCHEMBL7061490 | 0.82 | THRA (0.56) | THRATHRBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790978-B2 | 4-HYDROXY-3-ARYLSULFONYL, 3-AMINOSULFONYL OR 3-AMINOCARBONYL-PHENOXYANILINOCARBONYL-OPTIONAL ALKYLENE-CARBOXYLIC ACID OR CARBONYL-5-TETRAZOLES | NOVARTIS AG (CH) | 2004-09-14 | — | — | US | disclosed |
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045751-A1 | Thyromimetic organic compounds | TPO, THRA, LPO | THRA 2/4885THRB 7/4885L3MBTL1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.